Artiva Biotherapeutics, Inc. (ARTV) Stock Price & Analysis
Artiva Biotherapeutics, Inc. (ARTV) closed at USD 6.2 on Thursday, October 22, 2026, down 4.47% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 6.2; the Oct 22, 2026 session ranged USD 6.16–6.65 on volume of 393,893 shares. Market capitalization is —, with a 52-week range of USD 2.96–14.53 (NGM). Source: Nexqual, retrieved October 23, 2026 at 09:26 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ARTV.md
Key facts (ARTV)
- 1 of 80 tracked superinvestors hold ARTV (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Total return with dividends: 1Y +28.1% vs S&P 500 +14.9%; 5Y -48.3% vs S&P 500 +80.3%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ARTV)
| USD | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|
| Revenue | $33.5M | $251K | $0K | — |
| Operating income | -$30.7M | -$67.3M | -$89.8M | -$96.1M |
| Net income | -$28.7M | -$65.4M | -$83.9M | -$90.8M |
| EPS (diluted) | -$35.78 | -$5.81 | -$3.43 | — |
| Free cash flow | -$50.7M | -$55.7M | -$79.3M | -$76.9M |
| Operating margin | -91.6% | -26805.6% | — | — |
| Net margin | -85.8% | -26045.0% | — | — |
| Revenue growth | — | -99.3% | -100.0% | — |
| Cash + short-term investments | $77.0M | $185M | $108M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ARTV)
Superinvestors (SEC 13F-HR, Q2 2026) (ARTV)
1 of 80 tracked investors hold ARTV. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 0.07% | $25.3M | New position |
Analysts (ARTV)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-02 | Cantor Fitzgerald | Reiterated | Overweight | $40 |
Total return (dividends reinvested) (ARTV)
| 1Y (from 2025-10-23) | 5Y (from 2024-07-15) | |
|---|---|---|
| Total return | +28.1% | -48.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +28.2% | -25.2% |
| Volatility (annualized) | 121.6% | 123.3% |
| Max drawdown | -56.3% (Apr 2026→Oct 2026) | -90.7% (Sep 2024→Jun 2025) |
ARTV analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.53 | $-0.52 | +2.2% | $0 | 5 |
| Next quarter (ends Dec 2026) | $-0.58 | $-0.56 | +2.9% | $0 | 5 |
| Current fiscal year (ends Dec 2026) | $-2.51 | $-2.43 | +3.2% | $0 | 5 |
| Next fiscal year (ends Dec 2027) | $-2.61 | $-2.81 | -7.4% | $0 | 5 |
Key Statistics (as of October 23, 2026 at 09:26 UTC)
| Price | USD 6.2 |
|---|---|
| Change | ▼ 4.47% (down) |
| Previous Close | USD 6.2 |
| Open | USD 6.2 |
| Day Range | USD 6.16 – 6.65 |
| 52-Week Range | USD 2.96 – 14.53 |
| Volume | 393,893 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (ARTV)
Nexqual's technical model rates ARTV "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:26 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 30.14 (neutral) |
| vs SMA50 | Below (USD 8.91) |
| MACD | -0.72 (negative) |
Earnings (ARTV)
| EPS Estimate | USD -0.53 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.63 vs est -0.64 ▲ beat |
| 2026-03-31 | USD -0.95 vs est -0.84 ▼ miss |
| 2025-12-31 | USD -0.84 vs est -0.8 ▼ miss |
| 2025-09-30 | USD -0.88 vs est -0.8 ▼ miss |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financials & Fundamentals (ARTV)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -36.58% |
| Debt / Equity | 0.03 |
| Current Ratio | 24.16 |
| Total Cash | $349.39M |
| Total Debt | $9.85M |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Ownership (ARTV)
| Insider Ownership | +15.10% |
|---|---|
| Institutional Ownership | +84.30% |
| Shares Outstanding | 48.89M |
| Float | 19.53M |
| Short % of Float | +9.26% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALMS | Alumis Inc. | USD 6.82 | ▲ 0.15% |
| KYTX | Kyverna Therapeutics, Inc. | USD 5.73 | ▼ 1.88% |
| ANRO | Alto Neuroscience, Inc. | USD 22.2 | ▼ 4.8% |
| QTTB | Q32 Bio Inc. | USD 8.8 | ▲ 1.5% |
| MBX | MBX Biosciences, Inc. | USD 50.46 | ▼ 6.43% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:26 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt